JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease

Overview

The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are central mediators of cellular stress responses in [Parkinson's disease](/diseases/parkinsons-disease). These kinases drive [dopaminergic neuron](/cell-types/nigral-dopaminergic-neurons) death through apoptosis, microglial activation, and neuroinflammation. Multiple companies are actively developing inhibitors and modulators targeting these pathways for neuroprotection in PD.

The scientific rationale is strong: JNK3 (MAPK10) is neuron-specific and mediates dopaminergic apoptosis, while p38α (MAPK14) drives microglial pro-inflammatory cytokine production. Both pathways are activated by common PD stressors including mitochondrial dysfunction, oxidative stress, and alpha-synuclein aggregation. [@jnkrev][@p38rev]

Competitive Landscape

```mermaid
flowchart LR
subgraph JNK_Inhibitors
A1["CEP-1347\n(Fenebrutinib/Genentech)"]
A2["SP600125\n(Preclinical)"]
A3["JNK-IN-8\n(Preclinical)"]
A4["AAV-JNK3 shRNA\n(Gene therapy)"]
end

subgraph p38_Inhibitors
B1["Losmapimod\n(Fulcrum)"]
B2["PH-797804\n(Preclinical)"]
B3["SB239063\n(Preclinical)"]
B4["VX-745\n(Preclinical)"]
end

subgraph Dual_Modulators
C1["C21\n(Vicore - AT2/JNK)"]
C2["FUL-20002\n(Fulcrum - p38/JNK)"]
C3["Dual inhibitors\n(Preclinical)"]
end

Overview

The c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are central mediators of cellular stress responses in [Parkinson's disease](/diseases/parkinsons-disease). These kinases drive [dopaminergic neuron](/cell-types/nigral-dopaminergic-neurons) death through apoptosis, microglial activation, and neuroinflammation. Multiple companies are actively developing inhibitors and modulators targeting these pathways for neuroprotection in PD.

The scientific rationale is strong: JNK3 (MAPK10) is neuron-specific and mediates dopaminergic apoptosis, while p38α (MAPK14) drives microglial pro-inflammatory cytokine production. Both pathways are activated by common PD stressors including mitochondrial dysfunction, oxidative stress, and alpha-synuclein aggregation. [@jnkrev][@p38rev]

Competitive Landscape

Company Profiles

1. Fulcrum Therapeutics

Overview: Fulcrum Therapeutics (NASDAQ: FULC) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, developing small molecule therapeutics targeting genetically defined diseases. The company's lead program is losmapimod, a selective p38α/β MAPK inhibitor that has demonstrated neuroprotective effects in preclinical models and is currently in clinical trials for ALS. [@fulweb]

JNK/p38 Programs:

| Program | Target | Indication | Stage | Status |
|---------|--------|------------|-------|--------|
| Losmapimod (FUL-110) | p38α/β | [ALS](/diseases/amyotrophic-lateral-sclerosis) | Phase 2b | Recruiting (NCT04988915) |
| Losmapimod (FUL-110) | p38α/β | FSHD | Phase 3 | Completed (NCT04060468) |
| Losmapimod (FUL-110) | p38α/β | [Parkinson's Disease](/diseases/parkinsons-disease) | Preclinical | Research |
| FUL-20002 | p38/JNK dual | [Alzheimer's Disease](/diseases/alzheimers-disease) | Discovery | Preclinical |

Scientific Rationale for PD:

Losmapimod targets p38 MAPK in multiple ways relevant to PD:

• Microglial neuroinflammation: p38α drives TNF-α, IL-1β, and IL-6 production in activated microglia surrounding dopaminergic neurons [@p38micro]
• Neuronal survival: p38 inhibition protects against oxidative stress and mitochondrial dysfunction in [substantia nigra](/brain-regions/substantia-nigra) neurons
• BBB penetration: Losmapimod has demonstrated CNS exposure in multiple clinical trials (FSHD, ALS), addressing a key challenge for CNS kinase inhibitors
• Synergy potential: Combined with standard dopaminergic therapies, p38 inhibition may provide disease-modifying neuroprotection

• FSHD Phase 3 (NCT04060468): Completed, established safety in >600 patients with facioscapulohumeral muscular dystrophy
• ALS Phase 2b (NCT04988915): Ongoing, evaluating losmapimod's effects on functional decline [@losmapi]
• Safety profile: Generally well-tolerated with >1,000 patients treated across indications; liver function monitoring required

• Advantage: Extensive clinical safety database from FSHD and ALS trials enables faster PD development path
• Challenge: Previous p38 inhibitors (e.g., for rheumatoid arthritis) showed toxicity in chronic use, requiring careful dose optimization
• Opportunity: ALS trial results expected 2026 may validate the neuroprotective approach, de-risking PD development
• Risk: p38 inhibition may have narrow therapeutic window; BBB penetration adequate but not exceptional

• Market cap: ~$350M (NASDAQ: FULC)
• Cash runway: Through 2027
• Partnered with Roche (non-neurodegeneration) and has active business development discussions

Fulcrum is pursuing a staged approach to neurodegeneration:

2. Vicore Pharma

Overview: Vicore Pharma is a Swedish biopharmaceutical company headquartered in Gothenburg, developing drugs targeting the angiotensin II type 2 (AT2) receptor. Their lead compound C21 (buloxibutid) is an AT2 agonist that indirectly modulates JNK signaling. The company trades on Nasdaq Stockholm under the ticker VOR. [@vicorweb]

JNK/p38 Programs:

| Program | Target | Indication | Stage | Status |
|---------|--------|------------|-------|--------|
| C21 (Buloxibutid) | AT2/JNK | IPF | Phase 2 | Active (NCT04533090) |
| C21 (Buloxibutid) | AT2/JNK | Systemic Sclerosis | Phase 1 | Completed |
| C21 (Buloxibutid) | AT2/JNK | Parkinson's Disease | Preclinical | Research |
| VOR014 | AT2/JNK dual | Alzheimer's Disease | Discovery | Preclinical |

Mechanism of Action:

Vicore's approach is unique — rather than directly inhibiting JNK, C21 activates the AT2 receptor which:

Scientific Rationale for PD:

The AT2-JNK connection provides neuroprotection through several mechanisms:

• Dopaminergic neuron protection: C21 reduces JNK-mediated apoptosis in [substantia nigra](/brain-regions/substantia-nigra) neurons in MPTP and 6-OHDA models
• Anti-inflammatory effects: AT2 activation reduces microglial activation and associated neurotoxicity
• Neurotrophic effects: Promotes survival and differentiation of dopaminergic neurons
• BBB penetration: Demonstrated CNS exposure in preclinical models; oral bioavailability supports chronic dosing

• IPF Phase 2 (NCT04533090): Positive results demonstrating safety and efficacy in pulmonary fibrosis [@c21ipf]
• Systemic Sclerosis Phase 1: Completed, established safety profile
• Translation to PD: Preclinical data in PD models pending publication; IPF safety data supports rapid PD entry

• Advantage: Novel indirect JNK modulation may have better safety profile than direct kinase inhibitors; extensive safety data from IPF trials
• Challenge: AT2 receptor biology in CNS not fully characterized; may not achieve same JNK inhibition as direct inhibitors
• Opportunity: IPF Phase 2 success validates the AT2 approach; could enter PD trials by 2027
• Risk: AT2 agonism is a novel mechanism for neurodegeneration; clinical validation uncertain

• Market cap: ~SEK 1.5B (~$140M USD), VOR on Nasdaq Stockholm
• Cash runway: Through 2027
• EU Horizon 2020 grant recipient

3. Genentech / Roche (Historical)

Overview: Genentech developed CEP-1347, a mixed-lineage kinase (MLK) inhibitor that blocks JNK pathway activation upstream of JNK itself. While the original compound is no longer in development, it established important clinical precedent for JNK targeting in PD. [@cep1347]

Program History:

• Compound: CEP-1347 (Trenbryek)
• Mechanism: Mixed-lineage kinase (MLK) inhibitor — blocks MKK4/7 activation of JNK
• Clinical trial: Phase 2 in early Parkinson's disease (completed ~2002)
• Outcome: Did not meet primary endpoint; development discontinued
• Lessons: Established that upstream inhibition (MLK) may not achieve sufficient JNK blockade; also demonstrated the importance of patient selection and biomarker-driven development

CEP-1347's failure taught the field critical lessons:

4. Bristol-Myers Squibb (BMS)

Overview: BMS has explored JNK inhibitors for CNS indications through internal discovery and collaborations. Their p38 inhibitor programs in inflammation provided safety data that informed potential CNS applications.

Programs:

• BMS-986189 (p38 inhibitor): Preclinical studies in neuroinflammation
• BMS-582737 (p38 inhibitor): Previously in clinical trials for rheumatoid arthritis; provided safety database
• Collaborations: Multiple academic collaborations on MAPK pathways in neurodegeneration

BMS compounds, while not directly in PD trials, have contributed to understanding p38 inhibitor safety and pharmacology relevant to neurodegeneration.

5. Vertex Pharmaceuticals

Overview: Vertex has a robust kinase inhibitor discovery platform and has published on JNK inhibitors for neurodegeneration. Their expertise in structure-based drug design and high-throughput screening has produced novel JNK3-selective compounds.

Programs:

• JNK3-selective inhibitors: Multiple compounds in discovery with high selectivity for the neuron-specific JNK3 isoform
• CNS-optimized design: Focused on BBB penetration and kinase selectivity to minimize off-target toxicity
• Preclinical validation: Ongoing studies in PD models

Vertex's strategy focuses on:

6. Evotec

Overview: Evotec is a drug discovery company with a platform for identifying JNK and p38 inhibitors for neurodegeneration. They operate through partnerships with pharma companies rather than developing their own pipeline.

Partnerships:

• Academic collaborations: Multiple collaborations with universities on MAPK pathway biology
• Licensing deals: Providing hit-to-lead and lead optimization services for MAPK inhibitor programs
• iPSC platform: Using patient-derived neurons for phenotype-based screening of MAPK inhibitors

Evotec's contributions include:

• Development of patient-relevant screening assays using [iPSC](/experiments/ipsc-neurons-pd)-derived dopaminergic neurons
• Identification of novel JNK3-selective chemotypes
• Biomarker development for target engagement

7. Heptares (Heptares Therapeutics / Zealand Pharma)

Overview: Heptares has a structure-based drug design platform focused on GPCRs but has expanded into kinase inhibitors. Their approach uses structure-based design to create highly selective compounds.

Focus:

• p38 inhibitor optimization: Using X-ray crystallography to design p38 inhibitors with improved selectivity and CNS penetration
• Novel chemical matter: Identifying allosteric binding modes to achieve selectivity unavailable to ATP-competitive inhibitors

8. NeuMD (Academic Spinout)

Overview: NeuMD is a startup emerging from academic research on JNK inhibitors for PD. Founded by researchers from Harvard and MIT, it focuses exclusively on neuroprotective JNK targeting.

Approach:

• JNK3-targeted siRNA: AAV-delivered JNK3 knockdown for neuroprotection
• Small molecule JNK3 inhibitors: Novel chemotypes from academic drug discovery
• Combination with LRRK2: Exploring synergistic targeting of JNK and [LRRK2](/genes/lrrk2) pathways

Emerging Therapeutic Modalities

Gene Therapy Approaches

AAV-JNK3 shRNA:

• Delivered via AAV9 vector targeting neurons
• Long-lasting JNK3 knockdown in dopaminergic neurons
• Potential for single-treatment neuroprotection
• Challenges: CNS delivery, immune response, manufacturing

• In vivo CRISPR targeting JNK3 promoter
• Epigenetic silencing approaches
• Emerging but still preclinical [@jnkrev]

PROTAC Degraders

JNK PROTACs:

• Heterobifunctional molecules recruiting E3 ligase to degrade JNK
• Advantages over inhibitors: complete pathway suppression
• Challenges: CNS penetration, tissue selectivity

Peptide Inhibitors

Cell-penetrating JNK inhibitors:

• Peptide-based inhibitors derived from JNK-interacting proteins (JIPs)
• Higher selectivity than small molecules
• Challenges: stability, delivery, manufacturing costs

Clinical Trial Landscape (2026)

| Company | Compound | Indication | Phase | NCT | Status |
|---------|----------|------------|-------|-----|--------|
| Fulcrum | Losmapimod | ALS | Phase 2b | NCT04988915 | Recruiting |
| Fulcrum | Losmapimod | PD | Preclinical | — | Research |
| Vicore | C21 | IPF | Phase 2 | NCT04533090 | Active |
| Vicore | C21 | PD | Preclinical | — | Research |
| Various | Multiple | PD | Preclinical | — | Research |

Scientific Rationale Summary

JNK Targeting in PD

The scientific case for JNK inhibition in PD rests on several lines of evidence:

Genetic evidence:

• JNK3 knockout mice are resistant to MPTP toxicity [@mptpjnk]
• JNK pathway activation in PD patient [substantia nigra](/brain-regions/substantia-nigra) postmortem tissue
• [LRRK2](/genes/lrrk2) mutations associated with JNK pathway dysregulation [@lrrkjnk]

• JNK inhibitors protect dopaminergic neurons in toxin models (MPTP, rotenone, 6-OHDA)
• JNK3 gene therapy reduces neurodegeneration in animal models
• Neuroprotective effects demonstrated across multiple PD models [@neurojmk]

• CEP-1347 (MLK inhibitor) failed in Phase 2 — lesson: need better target engagement
• Direct JNK inhibitors have not yet reached PD clinical trials
• Biomarker development critical for patient selection and dose optimization

p38 Targeting in PD

p38 inhibition addresses neuroinflammation, a key contributor to PD progression:

Scientific basis:

• p38α drives microglial activation and pro-inflammatory cytokine production [@p38micro]
• p38 activity elevated in PD patient CSF and postmortem brain tissue
• p38 inhibitors reduce neuroinflammation in PD models

• Losmapimod has extensive safety data from non-CNS indications
• ALS trial may validate p38 inhibition approach for neurodegeneration
• PD represents larger market opportunity than rare diseases

• Chronic p38 inhibition may cause liver toxicity (lessons from RA trials)
• May need biomarker-driven patient selection
• Therapeutic window determination critical

Competitive Analysis

| Company | Compound | Mechanism | Stage | Strength | Risk |
|---------|----------|-----------|-------|----------|------|
| Fulcrum | Losmapimod | p38α/β inhibitor | Phase 2b (ALS) | Safety database, CNS data | Efficacy risk in ALS |
| Vicore | C21 | AT2/JNK modulator | Phase 2 (IPF) | Novel mechanism, safety | Unproven in CNS |
| Genentech | CEP-1347 | MLK inhibitor | Discontinued | Precedent | Failed Phase 2 |
| Vertex | JNK3 selective | JNK3 inhibitor | Discovery | Selectivity | Early stage |
| NeuMD | AAV-JNK3 | Gene therapy | Discovery | Targeting | Delivery challenges |

See Also

• [JNK/p38 MAPK Signaling in Parkinson's Disease](/mechanisms/jnk-p38-mapk-parkinsons) — Comprehensive mechanism page
• [Vicore Pharma](/companies/vicore-pharma) — AT2/JNK modulator developer
• [Fulcrum Therapeutics](/companies/fulcrum-therapeutics) — p38 MAPK inhibitor developer
• [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons) — Related mechanism
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons) — Upstream trigger
• [Apoptosis Pathways in PD](/mechanisms/apoptosis-parkinsons-disease) — Downstream effect of JNK
• [Therapeutic Targets in Parkinson's Disease](/therapeutics/parkinsons-disease-therapeutic-pipeline) — Overview of PD drug development

References

Pathway Diagram

The following diagram shows the key molecular relationships involving JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease discovered through SciDEX knowledge graph analysis: